Eye implant triggers sight improvements in GA at 36 months, pivotal study finds

Science Corporation's PRIMA retinal implant demonstrated sustained sight improvements in geographic atrophy patients at 36 months in its pivotal trial, according to newly published results. The findings arrive as the FDA reviews the device for US market approval. The implant addresses a key indication in age-related macular degeneration with no current treatment options.